GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Buyback Yield %

Biocure Technology (XCNQ:CURE) Buyback Yield % : 0.00 (As of May. 06, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Biocure Technology's current buyback yield was 0.00%.


Biocure Technology Buyback Yield % Historical Data

The historical data trend for Biocure Technology's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Buyback Yield % Chart

Biocure Technology Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.43 -3.58 -7.14 - -

Biocure Technology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biocure Technology's Buyback Yield %

For the Biotechnology subindustry, Biocure Technology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocure Technology's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Biocure Technology's Buyback Yield % falls into.


;
;

Biocure Technology Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Biocure Technology's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 1.410075
=0.00%

Biocure Technology's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 0.94005
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Biocure Technology Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocure Technology Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Executives
Konstantin Lichtenwald Director, Senior Officer

Biocure Technology Headlines